Publication

Article

CURE

Gastrointestinal Special Issue
Volume1
Issue 1

Medical Illustration: Targeting HER2 in Gastric Cancer

Author(s):

Erin Moore

For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.

For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.

For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.

ILLUSTRATION BY ERIN MOORE

ORIGINALLY PUBLISHED IN “GUT REACTION,” CURE WINTER 2009

*HER2 is also associated with breast cancer.

For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.

Articles in this issue
In Gastroesophageal Cancers, Better Prevention and Treatments Needed
Medical Illustration: Targeting HER2 in Gastric Cancer
Cholangiocarcinoma Research is Expanding, But Many Questions Are Still Unanswered
The Next Frontier: The Promise of Immunotherapy in Gastrointestinal Cancers
Gastrointestinal Stromal Tumors Already Proving to Be Treatable With Targeted Therapies
Searching on all Fronts: Changing the Outlook for Those With Pancreatic Cancer
Right in the Gut: New Clues About Preventing and Treating Gastric Cancer
An Insight Into Gastric Cancers and Life Without a Stomach
Changing Lives With Immunotherapy

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Kumar.
Image of Dr. Uboha.
Image of Dr. Kumar.
Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.
Bald Doctor.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Dr. Kim in an interview with CURE
Related Content
Clinical trials text.
April 21st 2025

Clinical Trials Enhance Care for Advanced Gastrointestinal Cancers

Spencer Feldman
Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Image of man holding stomach.
April 6th 2025

FDA Grants HLX22 Orphan Drug Designation for Gastric Cancer

Spencer Feldman
FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free survival and objective response.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Tovecimig elicited responses in biliary tract cancer in the COMPANION-002 study: © LIGHTFIELD STUDIOS - stock.adobe.com.
April 1st 2025

Second-Line Tovecimig Elicits Responses in Biliary Tract Cancer

Alex Biese
Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to COMPANION-002 study results.
Illustration of stomach.
March 31st 2025

Inside the Mind of a Bile Duct Cancer Survivor

Lisa Craine
I’ve spent 14 years navigating recovery, mental health challenges and giving back to the cancer community through patient mentorship.